BRAF and non-small cell lung carcinoma: Among these, NSCLC patients with BRAF mutations had more pleural metastasis (47.1% vs.16.8%, P = 0.005), and NRAS mutations had lung (60.0% vs.12.4%, P = 0.025) and pleural metastasis (60.0% vs.16.8%, P = 0.038).